Data Support Phenylephrine Efficacy, But More Studies Needed – NDAC
This article was originally published in The Tan Sheet
Executive Summary
FDA's Nonprescription Drugs Advisory Committee recommends additional studies on phenylephrine efficacy for treatment of nasal congestion, although members say current data support the efficacy of the OTC cough/cold ingredient
You may also be interested in...
J&J Zyrtec Pediatric Spoon Marks Increased Role For Dosing Innovations
Johnson & Johnson's introduction of pre-dosed spoons of children's Zyrtec reflects the growing attention the OTC market is paying to innovative solutions to dosing and safety issues -- particularly for pediatric populations
Congested OTC Monograph Process Can Leave Manufacturers Confused
The disparity between FDA's OTC monographs and up-to-date communications from the agency can create confusion for manufacturers, Office of New Drugs Director John Jenkins acknowledges
NDAC Chair Gives Vote Of Confidence To Simultaneous Voting
FDA's use of "simultaneous voting" at advisory committee meetings concerning OTC issues in December allowed members to vote free of influence by other members' votes while also proceeding with few technical problems